secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001193125-23-301185
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie extends option for Aldeyra's reproxalap with $5M fee
-----------------------------------------------------------

- AbbVie paid $5M non-refundable fee to extend option period for reproxalap co-development license.
- Exercise period now until 10 business days after FDA approval or 18 months from Oct 31, 2023.
- Option fee will be credited against upfront cash if License Agreement is signed.
- Reproxalap is Aldeyra's NDA-stage treatment for dry eye disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312523301185/0001193125-23-301185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312523301185/d603612d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-301185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer